April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Comparative Study Between Bevacizumab and 3-Epigallocatequin Gallate (EGCG) in the Regulation for VEGF and PEDF Expression in an Animal Model: Pilot Study
Author Affiliations & Notes
  • E. Romo-Garcia
    Retina, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • J. Flores-Estrada
    Retina, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • G. Salcedo-Villanueva
    Retina, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • J. Guerrero-Naranjo
    Retina, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • J. Jimenez-Sierra
    Retina, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • H. Quiroz-Mercado
    Denver Health Medical Center, Denver, Colorado
  • V. Morales-Canton
    Retina, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  E. Romo-Garcia, None; J. Flores-Estrada, None; G. Salcedo-Villanueva, None; J. Guerrero-Naranjo, None; J. Jimenez-Sierra, None; H. Quiroz-Mercado, None; V. Morales-Canton, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4744. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      E. Romo-Garcia, J. Flores-Estrada, G. Salcedo-Villanueva, J. Guerrero-Naranjo, J. Jimenez-Sierra, H. Quiroz-Mercado, V. Morales-Canton; Comparative Study Between Bevacizumab and 3-Epigallocatequin Gallate (EGCG) in the Regulation for VEGF and PEDF Expression in an Animal Model: Pilot Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4744.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the ability of bevacizumab and EGCG to regulate the expression of vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) on an intraocular inflammation model in rodents.

Methods: : We induced intraocular inflammation with intraocular injection of 0.1 ml (200mg/Kg) lipopolysacharides (LPS) in 18 Wistar rats. We divided our population in three groups. Group A received an intraperitoneal injection of EGCG (1ml of 300mg/ml), group B was injected with 1ml of intraperitoneal bevacizumab (2.25ml/ml) and group C received balanced salt solution as a control group. The eyes were enucleated 8hr, 12hr and 24hrs after the intraperitoneal injection. Tissue processing and RT-PCR were performed to measure VEGF and PEDF expression levels on the retina.

Results: : Expression levels of VEGF and PEDF were modified in each group. We observed that EGCG and bevacizumab induced an over-expression of PEDF and negative-expression of VEGF. At 8hrs in group A & B there was a lower expression of VEGF; at 12hrs in group A the expression of VEGF was higher than in group B, in which levels continued to be lower. At 24 hours, VEGF was over-expressed when compared with PEDF in the three groups.

Conclusions: : ECGC is capable of inhibit the expression of VEGF. Further more, electrophysiologic, histologic and dose evaluation studies are needed, before testing this drug in humans.

Keywords: drug toxicity/drug effects • retina • antioxidants 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×